

Importance of Microcystins/Nodularins Determination

Most of the world's population relies on surface freshwaters as its primary source of drinking water. The drinking water industry is constantly challenged with surface water contaminants that must be removed to protect human health. Toxic blooms of cyanobacteria (blue-green algae) are an emerging issue in the U.S. and the world because of increased source water nutrient pollution caused by eutrophication. Microcystins and Nodularins are cyclic toxin peptides. Microcystins (several structural variants or congeners are found) have been found in fresh water throughout the world and are produced by the genus *Microcystis*, *Anabaena*, *Oscillatoria*, *Nostoc*, *Anabaenopsis*, and terrestrial *Hapalosiphon*. Nodularins are produced by the genus *Nodularia* and are found in marine and brackish water. To date, approximately 80 variants of microcystin have been isolated. The most common variant is microcystin-LR. Other common microcystin variants include LA, YR, RR, and LW.

Acute poisoning of humans and animals constitutes the most obvious problem from toxic cyanobacterial blooms, and in several cases has led to death. These toxins mediate their toxicity by inhibiting liver function and are potent inhibitors of the serine/threonine protein phosphatases; therefore they may act as tumor promoters. To protect consumers from adverse health effects caused by these toxins, the WHO has proposed a provisional upper limit for microcystin-LR of 1.0 ppb (ng/L) in drinking water.

Human poisonings have often been suspected in the past but not confirmed due to lack of appropriate analytical techniques. In 1996, an episode of human intoxication by microcystins was first confirmed by Azevedo et al., after an outbreak of acute liver failure that resulted in the deaths of 76 patients at two dialysis centers in Caruaru, Brazil.


Performance Data

Test sensitivity: The detection limit for this assay based on MC-LR in serum is 0.40 ppb (µg/L).

Test reproducibility: Coefficients of variation (CVs) for standards: <10%, for samples: <15%.

Serum Recovery: Sample recovery: 70-130%.

Selectivity The assay exhibits very good cross-reactivity with all cyanobacterial cyclic peptide toxin congeners tested to date.



Specificity
The cross-reactivity of the Abraxis Microcystins ELISA for various Microcystins congeners:

Compound	X-reactivity (%)
Microcystins LR	100
Microcystins LW	102
Microcystins LF	72
Microcystins YR	76
Microcystins RR	67
Microcystins LA	66
Nodularins	78
N-hemi-ADDA	38
ADDA	15
D-Phenylalanine	NR
L-Phenylalanine	NR
DL-Phenylalanine	NR

NR = no reactivity up to 1000 ppb

General Limited Warranty/Disclaimer: Abraxis LLC warrants the products manufactured by the Company, against defects and workmanship when used in accordance with the applicable instructions for a period not to extend beyond the product's printed expiration date. Abraxis LLC makes no other warranty, expressed or implied. There is no warranty of merchantability or fitness for a particular purpose.

India Contact:

Life Technologies (India) Pvt. Ltd.

306, Aggarwal City Mall, Road No. 44, Pitampura, Delhi – 110034, India

Mobile: +91-98105-21400, Tel: +91-11-42208000, 8111, 8222, Fax: +91-11-42208444

Email: customerservice@lifetechindia.com, www.atzlabs.com ; www.lifetechindia.com

Microcystins ELISA for Serum (Microtiter Plate)

Enzyme-Linked Immunosorbent Assay for the Determination
of Microcystins and Nodularins in Human Serum Samples

Product No. 522031

1. General Description

The Abraxis Microcystins ELISA for Serum is an immunoassay for the quantitative and sensitive detection of microcystins and nodularins in human serum samples. For additional serum types (canine, etc.), please see the appropriate technical bulletin. A sample preparation and dilution is required prior to analysis. Positive samples should be confirmed by HPLC, protein phosphatase assay, or other conventional methods.

NOTE: This assay is intended for Research Use Only and not for in vitro diagnostic use.

2. Safety Instructions

The substrate solution contains tetramethylbenzidine (TMB) and the stop solution contains diluted sulfuric acid. Avoid contact of the TMB and stopping solution with skin and mucous membranes. If these reagents come in contact with skin, wash with water.

3. Storage and Stability

The Microcystins ELISA for Serum Kit should be stored in the refrigerator (4–8°C). Solutions should be allowed to reach room temperature (20–25°C) before use. Reagents may be used until the expiration date on the box. Consult state, local, and federal regulations for proper disposal of all reagents.

4. Test Principle

The test is a direct competitive ELISA which detects the presence of microcystins and nodularins in human serum. It is based on the recognition of microcystins, nodularins and their congeners by a monoclonal antibody. Microcystins, nodularins and their congeners, when present in a sample, and a microcystins-HRP analogue compete for the binding sites of anti-microcystins antibodies in solution. The microcystins antibodies are then bound by a second antibody (goat anti-mouse) immobilized on the plate. After a washing step and the addition of the substrate solution, a color signal is generated. The intensity of the blue color is inversely proportional to the concentration of the microcystins/nodularins present in the sample. The color reaction is stopped after a specified time and the color is evaluated using an ELISA reader. The concentrations of the samples are determined by interpolation using the standard curve constructed with each run.

5. Limitations of the Microcystins ELISA, Possible Test Interference

Only serum samples should be analyzed in the Microcystins Assay for Serum. Plasma samples should not be used, as interference from the clotting factors found in plasma will cause inaccurate results.

Due to the high variability of compounds that might be found in human serum samples, test interferences caused by matrix effects can not be completely excluded.

Mistakes in handling the test can also cause errors. Possible sources of such errors can include: Inadequate storage conditions of the test kit, wrong pipetting sequence or inaccurate volumes of the reagents, too long or too short incubation times during the immune and/or substrate reaction, and extreme temperatures during the test performance (lower than 10°C or higher than 30°C). The assay procedure should be performed away from direct sun light.

As with any analytical technique (GC, HPLC, etc.) positive results should be confirmed by an alternative method.

A. Materials Provided

1. Microtiter Plate coated with a second antibody (goat anti-mouse)
2. Serum Matrix Microcystins Standards (5): 0, 0.1, 0.25, 0.5, 1.0 ppb, 1 mL each
3. Serum Treatment Reagent A, 30 mL
4. Serum Treatment Reagent B, 1 mL
5. Monoclonal Anti-Microcystins in Serum Antibody Solution, 6 mL
6. Microcystins in Serum-HRP Conjugate Solution, 6 mL
7. Sample Diluent, 30 mL. Use to dilute samples (see Sample Preparation, Section C)
8. Wash Solution (5X) Concentrate, 100 mL
9. Color Solution (TMB), 16 mL
10. Stop Solution, 12 mL

B. Additional Equipment/Materials (not delivered with the test kit)

1. Micro-pipettes with disposable plastic tips (50-250 μ L)
2. Multi-channel pipette (50-250 μ L) or stepper pipette with plastic tips (50-250 μ L)
3. Microcentrifuge Tubes
4. Microcentrifuge
5. Overhead tube rotator or equivalent
6. Glass vials with teflon-lined caps
7. Microtiter plate washer (optional)
8. Microtiter plate reader (wavelength 450 nm)

C. Sample Preparation

1. Add 500 μ L of serum sample to a microcentrifuge tube.
2. Add 500 μ L of Serum Treatment Reagent A.
3. Add 20 μ L of Serum Treatment Reagent B. Vortex thoroughly. Mix using an overhead tube rotator for 15 minutes.
4. Centrifuge vial for 10 minutes at 10,000 g. A waxy precipitate will be visible at the bottom of the microcentrifuge tube and the supernatant should be clear (although not colorless). If the supernatant is not clear, centrifuge for an additional 10 minutes. Pipette supernatant into a clean glass vial.
5. Add 250 μ L of Sample Diluent to a second clean glass vial. Add 250 μ L of the treated serum to the Sample Diluent. Vortex thoroughly. The sample is then ready for analysis (see Assay Procedure, Section E).

The ELISA result will be multiplied by a factor of 4 to obtain the final microcystins concentration in the sample. Samples showing lower concentrations than standard 1 (0.1 ppb) should not be multiplied by the factor but should be reported as containing <0.4 ppb. Highly contaminated samples (those outside of the calibration range of the assay) must be diluted and re-analyzed.

D. Test Preparation

Micro-pipetting equipment and pipette tips for pipetting the standards and samples are necessary. We recommend using a multi-channel pipette or a stepping pipette for adding the antibody, enzyme conjugate, substrate solution, and the stop solution in order to equalize the incubation periods of the standard solutions and samples on the entire microtiter plate. Please use only the reagents and standards from one kit lot in one test, as they have been adjusted in combination. Read and understand the instructions and precautions given in this insert before proceeding.

1. Adjust the microtiter plate and the reagents to room temperature before use.
2. Remove the number of microtiter plate strips required from the foil bag. The remaining strips are stored in the foil bag and zip-locked closed. Store the remaining kit in the refrigerator (4-8°C).
3. The standard, antibody, enzyme conjugate, substrate and stop solutions are ready to use and do not require any further dilutions.
4. The wash solution is a 5X concentrated solution and must be diluted with deionized water. In a 1L container, dilute the 5X solution 1:5 (i.e. 100 mL of the 5X wash solution plus 400 mL of deionized water). The diluted solution is used to wash the microtiter wells.
5. The stop solution should be handled with care as it contains diluted H₂SO₄.

E. Assay Procedure

1. Add 100 μ L of the standard solutions and treated samples into the wells of the test strips according to the working scheme given. We recommend using duplicates or triplicates.

2. Add 50 μ L of the antibody solution to the individual wells successively using a multi-channel pipette or a stepping pipette. Cover the wells with parafilm or tape and mix the contents by moving the strip holder in a circular motion on the benchtop for 30 seconds. Be careful not to spill the contents. Incubate for 30 minutes at room temperature.
3. Add 50 μ L of the conjugate solution to the individual wells successively using a multi-channel pipette or a stepping pipette. Cover the wells with parafilm or tape and mix the contents by moving the strip holder in a circular motion on the benchtop for 30 seconds. Be careful not to spill the contents. Incubate for 90 minutes at room temperature.
4. After incubation, remove the covering and vigorously shake the contents of the wells into a sink. Wash the strips three times using the 1X washing buffer solution. Please use at least a volume of 250 μ L of washing buffer for each well and each washing step. Remaining buffer in the wells should be removed by patting the plate dry on a stack of paper towels.
5. Add 150 μ L of color solution to the wells using a multi-channel pipette or a stepping pipette. Cover the wells with parafilm or tape and mix the contents by moving the strip holder in a circular motion on the benchtop for 30 seconds. Be careful not to spill the contents. Incubate for 30 minutes at room temperature. Protect the strips from sunlight.
6. Add 100 μ L of stop solution to the wells in the same sequence as for the color solution using a multi-channel pipette or a stepping pipette.
7. Read the absorbance at 450 nm using a microplate ELISA photometer within 15 minutes after the addition of the stopping solution.

F. Evaluation

The evaluation of the ELISA can be performed using commercial ELISA evaluation programs (4-Parameter (preferred) or Logit/Log). For manual evaluation, calculate the mean absorbance value for each of the standards. Calculate the %B/B₀ for each standard by dividing the mean absorbance value for each standard by the Zero Standard (Standard 0) mean absorbance. Construct a standard curve by plotting the %B/B₀ for each standard on the vertical linear (y) axis versus the corresponding Microcystins concentration on the horizontal logarithmic (x) axis on graph paper. %B/B₀ for samples will then yield levels in ppb of Microcystins by interpolation using the standard curve. These values must then be multiplied by a factor of 4 to obtain the final microcystins concentration. Samples showing lower concentrations of Microcystins compared to Standard 1 (0.1 ppb) should not be multiplied by the factor but should be reported as containing <0.4 ppb. Samples showing a higher concentration than Standard 4 (1.0 ppb) must be diluted further to obtain accurate results.

G. Working Scheme

The microtiter plate consists of 12 strips of 8 wells, which can be used individually for the test. The **standards must be run** with each test. Never use the values of standards which have been determined in a test performed previously.

Std0-Sd4: Standards

Sample 1, Sample 2, etc.: Samples

	1	2	3	4	5	6	7	8	9	10	11	12
A	Std 0	Std 4										
B	Std 0	Std 4										
C	Std 1	Sample 1										
D	Std 1	Sample 1										
E	Std 2	Sample 2										
F	Std 2	Sample 2										
G	Std 3	etc.										
H	Std 3	etc.										

H. References

- (1) M. G. Weller, A. Zeck, A. Eikenberg, S. Nagata, Y. Ueno, and R. Niessner, Development of a Direct Competitive Microcystins Immunoassay of Broad Specificity. *Analytical Sciences*. 17, 2001, 1445-1448.
- (2) Worldwide Patenting PCT WO 01/18059 A2.
- (3) U.S. Patent Number 6,967,240.
- (4) J. Chen, P. Xie, L. Li, and J. Xu, First Identification of the Hepatotoxic microcystins in the Serum of a Chronically Exposed Human Population Together with Indication of Hepatocellular Damage. *Toxicological Sciences*. 108(1), 2009, 81-89.